Naka T - Search Results

1

Novel germline STAT3 gain-of-function mutation causes autoimmune diseases and severe growth failure.

Saito K, Fujimoto M, Funajima E, Serada S, Ohkawara T, Ishihara M, Yamada M, Suzuki H, Miya F, Kosaki K, Fujieda M, Naka T. Saito K, et al. Among authors: naka t. J Allergy Clin Immunol Glob. 2024 Jul 26;3(4):100312. doi: 10.1016/j.jacig.2024.100312. eCollection 2024 Nov. J Allergy Clin Immunol Glob. 2024. PMID: 39253104 Free PMC article.

2

LRG is a novel inflammatory marker clinically useful for the evaluation of disease activity in rheumatoid arthritis and inflammatory bowel disease.

Naka T, Fujimoto M. Naka T, et al. Immunol Med. 2018 Jun;41(2):62-67. doi: 10.1080/13497413.2018.1481582. Epub 2018 Sep 11. Immunol Med. 2018. PMID: 30938267 Free article.

3

Gene therapy with SOCS1 induces potent preclinical antitumor activities in oral squamous cell carcinoma.

Nakatani K, Serada S, Fujimoto M, Obata K, Ohkawara T, Sasabe E, Yamamoto T, Naka T. Nakatani K, et al. Among authors: naka t. J Oral Pathol Med. 2022 Feb;51(2):126-133. doi: 10.1111/jop.13268. Epub 2021 Dec 19. J Oral Pathol Med. 2022. PMID: 34878693

4

SOCS1 Gene Therapy for Head and Neck Cancers: An Experimental Study.

Kajiyama T, Serada S, Fujimoto M, Ohkawara T, Komori M, Hyodo M, Naka T. Kajiyama T, et al. Among authors: naka t. Anticancer Res. 2022 Jul;42(7):3361-3372. doi: 10.21873/anticanres.15823. Anticancer Res. 2022. PMID: 35790291

5

Tumor cell-expressed lipolysis-stimulated lipoprotein receptor negatively regulates T-cell function.

Funauchi M, Serada S, Hiramatsu K, Funajima E, Kanda M, Nagase Y, Nakagawa S, Ohkawara T, Fujimoto M, Suzuki Y, Ueda Y, Kimura T, Naka T. Funauchi M, et al. Among authors: naka t. Int J Cancer. 2024 Feb 1;154(3):425-433. doi: 10.1002/ijc.34738. Epub 2023 Sep 20. Int J Cancer. 2024. PMID: 37728485

6

Regulation of cytokine signaling by SOCS family molecules.

Fujimoto M, Naka T. Fujimoto M, et al. Among authors: naka t. Trends Immunol. 2003 Dec;24(12):659-66. doi: 10.1016/j.it.2003.10.008. Trends Immunol. 2003. PMID: 14644140 Review.

7

The involvement of leucine-rich α-2 glycoprotein in the progression of skin and lung fibrosis in bleomycin-induced systemic sclerosis model.

Nakajima H, Nakajima K, Serada S, Fujimoto M, Naka T, Sano S. Nakajima H, et al. Among authors: naka t. Mod Rheumatol. 2021 Nov;31(6):1120-1128. doi: 10.1080/14397595.2021.1883841. Epub 2021 Feb 17. Mod Rheumatol. 2021. PMID: 33535851

8

Leucine-rich α2-glycoprotein as a useful biomarker for evaluating disease activity in rheumatoid arthritis.

Fujimoto M, Hosono Y, Serada S, Suzuki Y, Ohkawara T, Murata O, Quick A, Suzuki K, Kaneko Y, Takeuchi T, Naka T. Fujimoto M, et al. Among authors: naka t. Mod Rheumatol. 2024 Aug 20;34(5):1072-1075. doi: 10.1093/mr/road112. Mod Rheumatol. 2024. PMID: 38141246 No abstract available.

9

Negative regulation of cytokine and TLR signalings by SOCS and others.

Naka T, Fujimoto M, Tsutsui H, Yoshimura A. Naka T, et al. Adv Immunol. 2005;87:61-122. doi: 10.1016/S0065-2776(05)87003-8. Adv Immunol. 2005. PMID: 16102572 Review. No abstract available.

10

[Role of IL-6 in the development and pathogenesis of CIA and EAE].

Fujimoto M, Serada S, Naka T. Fujimoto M, et al. Among authors: naka t. Nihon Rinsho Meneki Gakkai Kaishi. 2008 Apr;31(2):78-84. doi: 10.2177/jsci.31.78. Nihon Rinsho Meneki Gakkai Kaishi. 2008. PMID: 18446009 Free article. Review. Japanese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

580 results

Search Page

Filters